Susan Rosenbaum for Lauren Sciences LLC

Lauren Sciences LLC

Lauren Sciences developed novel V-Smart® Nanomedicine for AD, LAUR-601 (V-Smart®-BDNF for AD), with innovative V-Smart® Platform, to enable non-brain penetrant biologic, neurotrophin BDNF, as AD disease-modifying therapeutic, become FDA-approved drug for critical unmet medical need of all AD patients, at any stage, extend life and slow down, or reverse, AD. LAUR-601 encapsulates BDNF, is administered non-invasively, crosses BBB, delivers to/releases only in brain, specifically targets to/selectively releases at AD degenerating brain neurons. LAUR-601 is expected to prove effective in pre-clinical AD animal model studies and, thus, advance closer to clinical trials for all AD patients. LAUR-601 will significantly alter all AD patients’ health outcomes and lifespans, as it will lessen symptoms and delay disease progression, thus, provide unique benefits presently unavailable. Furthermore, LAUR-601 can be utilized as sub-platform/matrix for development of additional V-Smart® Nanomedicines for AD with other potential non-brain penetrant AD therapeutic agents.

Other Presentations

Aevum – Gail Chan, PhD – View


AKScientist – Aarti Kuver, PhD – View


AmyloiDia – Vladana Vukojevic, PhD View


ASDERA LLC – Knut Wittkowski, PhD – View


BIORCHESTRA Co., Ltd – Branden Ryu, PhD – View


BioTrillion, Inc. – Savan Devani, MS – View


BrainCures – Krzysztof Potempa, PhD – View


BrainTrip – Jurij Dreo, MD – View


Diadem – Simona Piccirella, PhD – View


Generian Pharmaceuticals, Inc. – Toren Finkel, MD, PhD – View


LumeNeuro – Ron Dennis – View


Marvel Biotechnology – Mark Williams, PhD, MBA – View


Memandis – Nareem Surya View


MGH/Harvard Medical School – Xudong Huang, PhD – View


Neuropath Therapeutics Limited – Julie Kelly, PhD – View


Oxford Brain Diagnostics Ltd – Steven Chance, PhD – View


University of Haifa – Nathaniel Gould, PhD – View


Winterlight Labs – Nicola Johnson, MS – View